Jihong Lin
Fuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
AI-driven multi-omics drug repurposing nominates AZD7762 as a multitarget inhibitor of IL22RA1 and FAM221A in esophageal squamous cell carcinoma.
Journal: NPJ precision oncology
Published: December 02, 2025
Impact of Interval to Esophagectomy After Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Cohort Analysis.
Journal: Thoracic cancer
Published: December 30, 2024
SORBS2-Mediated inhibition of malignant behaviors in esophageal squamous cell carcinoma through TIMP3.
Journal: International immunopharmacology
Published: June 21, 2024
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.
Journal: Nature medicine
Published: March 29, 2024
Hippo cooperates with p53 to maintain foregut homeostasis and suppress the malignant transformation of foregut basal progenitor cells.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 26, 2024
Elucidating the role of CYFIP2 in conferring cisplatin resistance in esophageal squamous cell carcinoma.
Journal: Scientific reports
Published: January 24, 2024
Radiologic Identification of Pathologic Tumor Invasion in Patients With Lung Adenocarcinoma.
Journal: JAMA network open
Published: October 16, 2023
Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?
Journal: Frontiers in immunology
Published: September 04, 2022
Neoadjuvant Immunotherapy Combined Chemotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study.
Journal: Frontiers in oncology
Published: October 18, 2021
Last Updated: 09/26/2026